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Purpose or Objective: To assess the safety, feasibility and 
efficacy of free-hand intra-operative multi-catheter breast 
implant and peri-operative high-dose rate brachytherapy 
(FHIOMBI-PHDRBT program) in early breast cancer treated by 
breast conservative surgery (BCS). 
 
Material and Methods: Patients with early breast cancer who 
were candidates for BCS and potential accelerated partial 
breast irradiation (APBI) were prospectively enrolled for the 
FHIOMBI-PHDRBT program. Patients suitable for APBI received 
PHDRBT (3.4 Gy BID for 10 in five days). Patients not suitable 
for APBI received PHDRBT as anticipatory boost (3.4 Gy BID 
for 4 in two days) followed by whole breast irradiation (WBI).  
 
Results: From November 2008 to January 2015, a total of 119 
patients were treated and 122 FHIOMBI procedures were 
performed. Median duration of FHIOMBI was 25 minutes. A 
median of 8 catheters (range 4-14) were employed. No 
intraoperative complications were observed. Severe early 
postoperative complications (bleeding) were documented in 2 
patients (1.6%), wound healing complications in 3 (2.4%), and 
infection (mastitis or abscess) in 2 (1.6%). Late mammogram 
follow-up revealed oil cysts in 56% of patients but 
symptomatic fat necrosis in only 2 patients (1.6%). PHDRBT 
was delivered as APBI in 88 patients (74%) and as a boost in 
31 (26%). The median CTV-T was 40.8 cc (range 12.3-160.5), 
median D90 of 3.32 Gy (range 3.11-3.85), median DHI 0.72 
(range 0.48-0.82) median D10 in high-risk skin zone 1.94 Gy 
(range 0.92-3.37). With a median follow-up of 35 months 
(range 5.9-80.9) in the whole group and 37.7 months (range 
7.6-80.9) in APBI patients, no local, elsewhere or regional 
failures were observed, only one distant failure in PHDRBT 
boost was documented. Cosmetic outcomes were evaluated 
in APBI patients as excellent (42.0%), very good (46.0%), fair 
(10.0%) or poor (2.0%). 
 
Conclusion: The FHIOMBI-PHDRBT program does not add 
complications to conservative surgery, it adapts to breast 
size and location of the tumor, fulfilling at the same time 
prescription requirements and constraints. It allows an 
exquisite selection of APBI patients and offers excellent 
results in disease control and cosmetics. It also offers logistic 
advantages as it dramatically shortens the time of local 
treatment and avoids further invasive procedures. 
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Purpose or Objective: To describe early observations of a 
multi-center study utilizing a single fraction of intra-
operative radiation therapy (IORT) using the Xoft® Axxent® 
Electronic Brachytherapy System® (eBx®) immediately 
following surgical resection of early stage breast cancer. 
 
Material and Methods: 727 subjects have been treated at 25 
hospitals. Upon meeting entry criteria, patients underwent 
partial mastectomy. While in the operating room a balloon 
applicator was placed in the lumpectomy cavity and inflated 
with saline (30–75 cc). The skin was closed over the balloon, 
a balloon surface-to-skin distance of >1.0 cm was confirmed, 
and a single fraction of IORT was delivered to the 
lumpectomy cavity. The prescribed dose was 20 Gy at the 
balloon applicator surface; the mean treatment time was 
10.3 minutes. After treatment, the balloon was deflated and 
removed, and skin sutured. 
 
Results: 726 subjects received the prescribed dose of 20 Gy; 
one received 21 Gy. 56 are removed from the primary 
analysis post-IORT due to subsequent whole breast irradiation 
(N=37), positive lymph nodes (N=7), positive surgical margins 
(N=4), re-excision (N=4), inadequate skin bridge (N=2), 
inadequate balloon conformance (N=1), and other (N=4). 
These subjects will be followed for the duration of the study. 
An additional 60 subjects have withdrawn, leaving 667 active 
subjects. The mean patient age is 65 years (44-88). 148 
subjects (20%) had ductal carcinoma in situ, 550 (75%) had 
invasive ductal carcinoma, 28 (5%) were unknown. DCIS 
nuclear grade was high (N=55), intermediate (N=64) and low 
(N=27); 2 were unknown. Invasive cancer was Grade 1-2 in 
465/550 cases. 93% (N=676) had T1 lesions, 7% (N=51) had T2 
lesions. Mean tumor size is 10.53 mm ± 8.3 mm. Mean follow-
up is 336 days (4-1096). Only 125/926 (13.5%) of the reported 
adverse events were Grade 2 or higher. The most frequent 
AEs are seroma (15.4%), breast pain (14.1%), erythema 
(10.7%), and induration (8.5%). Cosmesis was excellent-to-
good in over half (65%) of the cases. There have been six (6) 
deaths (aortic aneurysm; heart attack; pneumonia; liver 
cancer; 2 unknown causes) and only one (1) recurrence 
reported to-date. 
 
Conclusion: IORT using the Xoft System as part of the 
conservative treatment of breast cancer is safe, with low 
morbidity. Early results from this multi-center trial 
demonstrate this short, convenient course of radiation 
therapy for select patients with early stage breast cancer has 
excellent-to-good cosmetic results and a low rate of low-
grade adverse events. 
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Purpose or Objective: Purpose: The study we report is for 
early stage breast cancer and is a multicentre clinical 
investigation of PBI achieved by interstitial HDR 
brachytherapy with intraoperative placement of catheters. 
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The aim of this study is to evaluate feasibility, acute and late 
toxicities and cosmetic results with a long follow-up. 
 
Material and Methods: Methods and materials: From January 
2005 to December 2013 a total of 445 patients were enrolled 
in the study, implanted during surgery and treated using a 
microSelectron-HDR brachytherapy Unit. The median age of 
the patients was 65 years (range 48-88 years). All those 
enrolled had an infiltrating ductal carcinoma in the absence 
of an extensive intraductal component and with clear surgical 
margins. Sentinel node biopsy was positive in 19,9% of 
patients and the 76,7% of patients have had estrogen 
therapy, 15,9% have had adjuvant chemotherapy. In the 
95.75 of patient the histology was ductal infiltranting 
carcinoma, in the 51% of cases the stage was T1b, in the 35% 
was T1c. Adjuvant chemotherapy was given to 15,9% of 
patients and hormone therapy to 76,7% of patients. The 
reference dose is taken as 85% of the mean basal dose. A 
reference dose of 35 Gy (3.5 Gy in two fractions per day) was 
delivered to 17% and a dose of 32 Gy (4 Gy in two fractions 
per day) to 83%. The average time of overall treatment was 
five days (76,8% in 4-5 days and 23,2% in 6-7 day); the 
difference is due to festivity and hospital provenience. 
Catheters were implanted (average of 14) guided by 
templates in most cases with distance between holes of 16 
mm, in a double or triple-plane arrangement in 99% of 
patients. The mean volume surrounded by the prescription-
isodose was 69,2 cc (range 13-129 cc). The treatment plans 
were evaluated in terms of skin dose, natural dose-
histogram, quality (mean 2,15 - range 1-3.04) and uniformity 
(mean 2.53 and range 1-3.54) index. 
 
Results: Results: The average overall treatment time is 
five/six days starting from implant commencement. The 
incidence of acute and late toxicities are given in Table I. 
Cosmetic results were excellent/good in 81% of patients. In a 
follow-up of 96 months we observed a local control of 7,7% 
and in 1,5% metastatic disease. 
Table II. Acute and late toxicities. 
 
 
Conclusion: Conclusions: The initial data demonstrates that 
an interstitial perioperative brachytherapy implant is a 
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Purpose or Objective: To assess the outcome of patients 
treated with CT guided HDR brachytherapy for cervical 
cancer 
 
Material and Methods: The records for 100 consecutive 
patients treated in our centre were reviewed. All patients 
prior to treatment had a biopsy for diagnosis, and a staging 
pelvic MRI and whole body PET scan. Treatment comprised of 
EBRT to a dose of 45Gy in 25 fractions given to the pelvis ± 
para-aortics with concurrent cisplatin chemotherapy. The 
brachytherapy was delivered in 3 fractions using a ring and 
tandem applicator with CT planning of each individual 
fraction and using information from a pre-implant planning 
MRI. The aim is to achieve HRCTV d90 of >80Gy whilst staying 
within the published parameters for the OARs. The outcomes 
in terms of survival and pattern of relapse were recorded and 
correlated with the HRCTV d90 and volume, and the dose to 
the OARs. The unpaired t-test and pearson correlation 
coefficient were used with 2-tailed significance testing level 
of 0.05. 
 
Results: The median follow up was 32 months with a median 
age at time of treatment of 44 years (21 – 85 years). Most 
patients were diagnosed with squamous cell carcinoma (77) 
or adenocarcinoma (17), 3 patients had an adenosquamous 
carcinoma and there were 4 cases with unusual histological 
findings of small cell, serous papillary (2) or neuroendocrine 
carcinomas. At the time of follow up 78 patients are alive, 21 
died from disease and 1 died from unrelated causes. The 
median time to relapse was 8 months (range 1-23 months). 
There were 2 cases of isolated pelvic central recurrences, 11 
cases of pelvic and distant metastases and 8 cases with only 
distant disease. The median d90 was 83.9Gy and the mean 
HRCTV volume was 32.3cm3 (range 9.0 – 83.9cm3). There was 
a statistically significant difference in d90 between patients 
with relapse v.s. no relapse (t= 2.49, p=0.019) and there was 
a strong negative correlation between the HRCTV volume and 
the d90 (r= -0.48, p<0.0001). The median doses to the OARs: 
rectum 60.3Gy (46.8 – 74.1Gy), sigmoid 66.9Gy (46 – 76.5Gy), 
small bowel 59.1Gy (43.7 – 75Gy) and bladder 75Gy (51.4 – 
93.9Gy). There were 3 cases with grade 3-4 toxicity that 
could be related to the brachytherapy: 1 vesico-vaginal 
fistula, 1 recto-vaginal fistula, and 1 post treatment 
hydronephrosis. 
 
Conclusion: CT guided cervical brachytherapy allows the 
delivery of adequate radiation doses to the HRCTV as shown 
by our acceptable local control and toxicity rates. The 
pattern of distant disease in the majority of relapses 
indicates that despite optimal staging investigations and 
adequate radiation doses to the HRCTV, distant undetected 
microscopic disease will still determine the outcome in a 
proportion of cases. 
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Purpose or Objective: Image guided plan optimisation with 
MRI and CT for interstitial and intracavitary brachytherapy is 
an established technique in treating cervical cancer. The 
purpose of this current study is to assess the feasibility of 
boosting the dose to GTV(BT) to 140% of the HRCTV 
prescription dose, while keeping critical structure dose 
volume histograms within tolerance. 
 
Material and Methods: 14 MRI/CT guided treatment plans 
were analysed in this study. Patients were treated using 
either Vienna-style ring applicator or Fletcher-style 
applicator, with or without interstitial catheters. The median 
age of the patients was 51.5 years (range 25-80.2 years). One 
patient had FIGO Stage IB cancer, 10 had stage IIB cancer and 
3 had stage IIIB cancer. All received IMRT external beam 
